Antibiotics
|
Antibiotics
|
Antibiotics
|
Antibiotics
|
Antibiotics
|
Meropenem with varborbactam
|
Metoprolol
|
Increases the concentration
|
Monitor for toxicity
|
U
|
Ceftazidime with avibactam
|
No interaction listed
|
No interaction listed
|
No interaction listed
|
No interaction listed
|
Cefoxitin
|
No interaction listed
|
No interaction listed
|
No interaction listed
|
No interaction listed
|
Tobramycin
|
Digoxin
|
Increases the concentration
|
Regular monitoring and dose adjustment recommended
|
+
|
|
Furosemide & Torasemide
|
increases the risk of nephrotoxicity and ototoxicity
|
Advised to avoid
|
++
|
Colistimethate Sodium (Colomycin)
|
No interaction listed
|
No interaction listed
|
No interaction listed
|
No interaction listed
|
Piperacillin with tazobactam (Tazocin)
|
Warfarin
|
Alters the anti-coagulant effect of warfarin
|
Regular INR monitoring & dose adjustment advised
|
+++
|
Azithromycin
|
Apixaban, Dabigatran & Edoxaban
|
Predicted to increase the exposure
|
No recommendation given
|
++
|
|
Digoxin
|
Increases concentration
|
Advised to monitor digoxin levels
|
+++
|
|
Nadolol
|
Predicted to increase exposure
|
No recommendation given
|
++
|
|
Ticagrelor
|
Increases the exposure
|
Advised to use with caution or avoid
|
+++
|
Minocycline
|
Pravastatin, Rosuvastatin & Simvastatin
|
Increased risk of hepatotoxicity
|
Advised to use with caution
|
U
|
|
Warfarin
|
Increases the anti-coagulant effect of Warfarin
|
Advised to monitor INR
|
+++
|
Aztreonam
|
No interaction listed
|
No interaction listed
|
No interaction listed
|
No interaction listed
|
Bronchodilators
|
Bronchodilators
|
Bronchodilators
|
Bronchodilators
|
Bronchodilators
|
Salbutamol
|
Bendroflumethiazide, Bumetanide, Chlortalidone, Furosemide,
Indapamide, Metolazone, Torasemide
|
Increases the risk of hypokalaemia
|
No recommendation given
|
U
|
|
Digoxin
|
Increases the risk of digoxin toxicity
|
Advised to use with caution
|
+++
|
|
Dronedarone, Flecainide, Quinine, Ranolazine, Sotalol
|
Predicted to cause hypokalaemia (potentially increasing the risk of
torsade de pointes)
|
No recommendation given
|
+++
|
CFTR Modulators |
CFTR Modulators |
CFTR
Modulators |
CFTR Modulators |
CFTR
Modulators |
Ivacaftor
|
Dabigatran, Edoxaban & Rivaroxaban
|
Predicated to increase the exposure
|
Advised to use with caution
|
++
|
|
Digoxin
|
Slightly increases the exposure
|
Advised to use with caution
|
++
|
|
Dronedarone
|
Increases exposure of Ivacaftor
|
Advised to use with caution
|
++
|
|
Verapamil
|
Increases the exposure of Ivacaftor
|
Dose adjustment recommended
|
++
|
|
Warfarin
|
Increases exposure
|
Advised to monitor INR
|
++
|
Ivacaftor with tezacaftor and Elexacaftor (Kaftrio)
|
All interactions included above for Ivacaftor
|
All interactions included above for Ivacaftor
|
All interactions included above for Ivacaftor
|
All interactions included above for Ivacaftor
|
|
Atorvastatin, Pravastatin, Rosuvastatin & Simvastatin
|
Increases exposure
|
Advised to use with caution
|
++
|
|
Diltiazem
|
Increases exposure
|
Advised to use with caution
|
+++
|
Enzymes
|
Enzymes
|
Enzymes
|
Enzymes
|
Enzymes
|
Dornase Alfa
|
No interaction listed
|
No interaction listed
|
No interaction listed
|
No interaction listed
|
Steroids |
Steroids |
Steroids |
Steroids |
Steroids |
Prednisolone
|
Amiodarone & Dronedarone
|
Predicted to cause hypokalaemia & increases the risk of torsade de
pointes.
|
No recommendation given
|
+++
|
|
Aspirin
|
Increases concentration & risk of gastrointestinal bleeding
|
No recommendation given
|
++
|
|
Bumetanide, Chlorothiazide, Chlortalidone, Furosemide,
Indapamide, Metolazone & Torasemide
|
Increases the risk of hypokalaemia
|
Advised to use with caution
|
U
|
|
Digoxin
|
Increases the risk of digoxin toxicity
|
Advised to use with caution
|
+++
|
|
Nicorandil
|
Increases the risk of gastrointestinal perforation
|
Advised to use with caution
|
+++
|
|
Ranolazine
|
Predicted to cause hypokalaemia & increases the risk of torsade de
pointes
|
Advised to use with caution
|
+++
|
|
Warfarin
|
Increases the effects of Warfarin
|
Advised to monitor INR
|
++
|